M Weinblatt

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint RAPID: rheumatoid arthritis
    Michael E Weinblatt
    Harvard Medical School, Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, Boston, MA, USA
    J Fam Pract 56:S1-7; quiz S8. 2007
  2. doi request reprint Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial
    Michael E Weinblatt
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    J Rheumatol 40:369-78. 2013
  3. pmc Methotrexate in rheumatoid arthritis: a quarter century of development
    Michael E Weinblatt
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Trans Am Clin Climatol Assoc 124:16-25. 2013
  4. pmc Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis
    Altan Ercan
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, One Jimmy Fund Way, Smith 516C, Boston, MA 02115 USA
    Arthritis Res Ther 14:R43. 2012
  5. pmc Sustained rheumatoid arthritis remission is uncommon in clinical practice
    Femke H M Prince
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Arthritis Res Ther 14:R68. 2012
  6. doi request reprint Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program
    Michael E Weinblatt
    Brigham and Women s Hospital, Boston, MA, USA
    J Rheumatol 40:787-97. 2013
  7. doi request reprint Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study
    Michael E Weinblatt
    Division of Rheumatology and Immunology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Arthritis Care Res (Hoboken) 65:362-71. 2013
  8. doi request reprint Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial
    Michael E Weinblatt
    Department of Rheumatology, Brigham and Women s Hospital, 75 Francis St, Boston, Massachusetts, 02115, USA
    Ann Rheum Dis 72:381-9. 2013
  9. pmc Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study
    Michael E Weinblatt
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 65:28-38. 2013
  10. doi request reprint Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
    Michael E Weinblatt
    Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Rheumatology (Oxford) 51:2204-14. 2012

Detail Information

Publications69

  1. ncbi request reprint RAPID: rheumatoid arthritis
    Michael E Weinblatt
    Harvard Medical School, Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, Boston, MA, USA
    J Fam Pract 56:S1-7; quiz S8. 2007
  2. doi request reprint Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial
    Michael E Weinblatt
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    J Rheumatol 40:369-78. 2013
    ..To assess the influence of fostamatinib on patient-reported outcomes (PRO) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX)...
  3. pmc Methotrexate in rheumatoid arthritis: a quarter century of development
    Michael E Weinblatt
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Trans Am Clin Climatol Assoc 124:16-25. 2013
    ..MTX therapy has been a major advance in the treatment of rheumatoid arthritis and is now the cornerstone of therapy. ..
  4. pmc Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis
    Altan Ercan
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, One Jimmy Fund Way, Smith 516C, Boston, MA 02115 USA
    Arthritis Res Ther 14:R43. 2012
    ..We examined whether a proxy measure for galactosylation of IgG N-glycans could predict response to therapy or was differentially affected by methotrexate (MTX) or TNF blockade...
  5. pmc Sustained rheumatoid arthritis remission is uncommon in clinical practice
    Femke H M Prince
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Arthritis Res Ther 14:R68. 2012
    ..Remission is an important goal of therapy in rheumatoid arthritis (RA), but data on duration of remission are lacking. Our objective was to describe the duration of remission in RA, assessed by different criteria...
  6. doi request reprint Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program
    Michael E Weinblatt
    Brigham and Women s Hospital, Boston, MA, USA
    J Rheumatol 40:787-97. 2013
    ..To assess the overall safety, including rare events, of intravenous (IV) abatacept treatment in rheumatoid arthritis (RA)...
  7. doi request reprint Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study
    Michael E Weinblatt
    Division of Rheumatology and Immunology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Arthritis Care Res (Hoboken) 65:362-71. 2013
    ....
  8. doi request reprint Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial
    Michael E Weinblatt
    Department of Rheumatology, Brigham and Women s Hospital, 75 Francis St, Boston, Massachusetts, 02115, USA
    Ann Rheum Dis 72:381-9. 2013
    ..Evaluate the efficacy of intravenous golimumab 2 mg/kg+methotrexate (MTX) in patients with active rheumatoid arthritis (RA) receiving MTX...
  9. pmc Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study
    Michael E Weinblatt
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 65:28-38. 2013
    ..Therefore, this study was undertaken as the first head-to-head comparison of subcutaneous (SC) abatacept and SC adalimumab, both administered along with background methotrexate (MTX), for the treatment of RA...
  10. doi request reprint Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
    Michael E Weinblatt
    Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Rheumatology (Oxford) 51:2204-14. 2012
    ..To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA...
  11. doi request reprint Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis
    Michael E Weinblatt
    Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Arthritis Care Res (Hoboken) 63:373-82. 2011
    ..To evaluate the long-term safety and efficacy of etanercept therapy in rheumatoid arthritis (RA) patients...
  12. pmc Validation of rheumatoid arthritis diagnoses in health care utilization data
    Seo Young Kim
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Arthritis Res Ther 13:R32. 2011
    ..Health care utilization databases have been increasingly used for studies of rheumatoid arthritis (RA). However, the accuracy of RA diagnoses in these data has been inconsistent...
  13. pmc Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study
    Yvonne C Lee
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, 75 Francis Street, PBB B3, Boston, MA, USA
    Arthritis Res Ther 13:R83. 2011
    ..We assessed the prevalence of pain in RA patients in remission according to the Disease Activity Score (DAS28-CRP4) and the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria...
  14. pmc The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28
    Masayo Sato
    Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    Arthritis Res Ther 8:R57. 2006
    ..The RARBIS has both face and convergent validity for patients with RA and relevant subgroups and may have application for medical records studies in patients with RA...
  15. pmc Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study
    Gladys Ting
    Department of Medicine, Division of Pharmacoepidemiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120, USA
    Arthritis Res Ther 10:R95. 2008
    ....
  16. doi request reprint An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
    Michael E Weinblatt
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:1303-12. 2010
    ..The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy...
  17. pmc Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
    Michael Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Ann Rheum Dis 66:228-34. 2007
    ....
  18. ncbi request reprint Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study
    M Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 54:2807-16. 2006
    ....
  19. doi request reprint Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study
    Michael E Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 58:1921-30. 2008
    ....
  20. doi request reprint Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate
    Michael E Weinblatt
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Rheumatol 38:242-6. 2011
    ..To identify factors associated with radiographic progression at 52 weeks in patients with rheumatoid arthritis (RA) after 12 weeks of methotrexate (MTX) therapy...
  21. ncbi request reprint Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial
    Michael E Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 48:35-45. 2003
    ..To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal tumor necrosis factor alpha antibody, in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite treatment with MTX...
  22. pmc Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
    M E Weinblatt
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, 75 Francis St, Boston, MA, USA
    Ann Rheum Dis 65:753-9. 2006
    ..To evaluate the efficacy and safety of adalimumab plus methotrexate (MTX) given for up to 4 years in patients with active, longstanding rheumatoid arthritis...
  23. ncbi request reprint The best of times, the worst of times: rheumatology 2001
    Michael E Weinblatt
    Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Arthritis Rheum 46:567-73. 2002
  24. pmc Rheumatoid arthritis in 2003: where are we now with treatment?
    M E Weinblatt
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Rheum Dis 62:ii94-6. 2003
  25. ncbi request reprint Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 56:1754-64. 2007
    ..To assess the association between the initiation of anti-tumor necrosis factor alpha (anti-TNFalpha) therapy and the risk of serious bacterial infections in routine care...
  26. ncbi request reprint Performance of a rheumatoid arthritis records-based index of severity
    Gladys Ting
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    J Rheumatol 32:1679-87. 2005
    ..To assess the performance of a rheumatoid arthritis (RA) records-based index of severity (RARBIS) developed by a Delphi panel process in a cohort of patients with RA...
  27. ncbi request reprint Rheumatoid arthritis: more aggressive approach improves outlook
    Michael E Weinblatt
    Brigham and Women s Hospital, Rheumatology Immunology Allergy, Arthritis Center, Harvard Medical School, Boston, Mass 02115, USA
    Cleve Clin J Med 71:409-13. 2004
    ..Other agents can be added to or used in place of methotrexate, such as a biologic response modifier that regulates the proinflammatory cytokine tumor necrosis factor-alpha...
  28. pmc Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy
    Jing Cui
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 62:1849-61. 2010
    ..The aim of the present study was to test established RA genetic risk factors to determine whether the same alleles also influence the response to anti-TNF therapy...
  29. doi request reprint Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial
    Michael E Weinblatt
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Arthritis Rheum 58:3309-18. 2008
    ..R788, a prodrug of active metabolite R406, has been shown to be an inhibitor of Syk kinase, active in a variety of in vitro and in vivo models, suggesting potential activity in the treatment of rheumatoid arthritis (RA)...
  30. ncbi request reprint Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study
    Alyssa K Johnsen
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Rheumatol 33:659-64. 2006
    ..To assess the safety and efficacy of etanercept 50 mg administered twice weekly versus 25 mg administered twice weekly as monotherapy in patients with tumor necrosis factor-alpha (TNF-alpha) blocker-naäve active rheumatoid arthritis (RA)...
  31. pmc Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis
    Soko Setoguchi
    Divisions of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard MedicalSchool, Boston, MA 02130, USA
    Am Heart J 156:336-41. 2008
    ..Although TNFAs had significant benefits in treating rheumatoid arthritis (RA), little is known whether the drugs pose an increased risk of HF in older patients with RA...
  32. pmc Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis
    Jing Cui
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Med 15:136-43. 2009
    ..We identified a SNP in moderate linkage disequilibrium (LD) with HLA-DR3, which may influence anti-CCP titer independently of the HLA-SE...
  33. pmc The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis
    Daniel H Solomon
    Brigham and Women s Hospital, Division of Rheumatology, Boston, Massachusetts 02115, USA
    Arthritis Rheum 60:1624-31. 2009
    ..The aim of this study was to determine whether lower BMD is associated with higher erosion scores among patients with RA...
  34. pmc Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk
    Soumya Raychaudhuri
    Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Nat Genet 41:1313-8. 2009
    ..0008 replication, P = 4 x 10(-6) overall) and FCGR2A (rs12746613, P = 0.0022 replication, P = 2 x 10(-5) overall). Many of these loci are also associated to other immunologic diseases...
  35. pmc Hand bone mineral density is associated with both total hip and lumbar spine bone mineral density in post-menopausal women with RA
    Sonali P Desai
    Brigham and Women s Hospital, PBB B3, Boston, MA 02115, USA
    Rheumatology (Oxford) 49:513-9. 2010
    ..RA is associated with localized bone loss in the hands, as well as generalized osteoporosis. We evaluated the relationship between hand digital X-ray radiogrammetry BMD (DXR-BMD) and total hip and lumbar spine BMD...
  36. doi request reprint Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study
    Christine K Iannaccone
    Department of Medicine, Brigham and Women s Hospital, PBB B3, 75 Francis Street, Boston, MA 02115, USA
    Rheumatology (Oxford) 50:40-6. 2011
    ....
  37. doi request reprint Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor
    Derrick J Todd
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Arthritis Rheum 63:894-903. 2011
    ..The purpose of this study was to assess whether these factors confound multiplex-based immunoassays, which are used with increasing frequency to measure cytokine and chemokine analytes in patients with rheumatoid arthritis (RA)...
  38. pmc Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis
    Sandeep K Agarwal
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Rheumatol 35:1737-44. 2008
    ..Our goal was to determine the discontinuation rate of TNF inhibitors and identify predictors associated with discontinuation...
  39. pmc Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate
    Yvonne C Lee
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Rheumatology (Oxford) 48:613-7. 2009
    ..We examined the association between candidate single nucleotide polymorphisms (SNPs) and disease activity in RA patients on MTX...
  40. ncbi request reprint Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel
    Danielle Cabral
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Arthritis Rheum 53:61-6. 2005
    ..To develop a set of indicators for assessing the severity of rheumatoid arthritis (RA) through medical records...
  41. ncbi request reprint Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis
    Elizabeth Benito-Garcia
    Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Rheumatol 33:1275-81. 2006
    ..We investigated whether patients with RA taking MTX with a higher dietary caffeine intake have a worse clinical response to MTX than those with a lower intake...
  42. ncbi request reprint Principal components analysis corrects for stratification in genome-wide association studies
    Alkes L Price
    Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Genet 38:904-9. 2006
    ..Our simple, efficient approach can easily be applied to disease studies with hundreds of thousands of markers...
  43. ncbi request reprint Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis
    Soko Setoguchi
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02130, USA
    Arthritis Rheum 54:2757-64. 2006
    ..This study was undertaken to estimate the association between treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and development of cancer in patients with RA...
  44. ncbi request reprint Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1771-81. 2006
    ..The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac...
  45. ncbi request reprint Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis
    Daniel H Solomon
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02120, USA
    Arthritis Rheum 54:3790-8. 2006
    ..This study was undertaken to investigate the effects of various immunosuppressive medications on the risk of cardiovascular events among a group of older patients with RA...
  46. ncbi request reprint Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries
    Daniel H Solomon
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Arthritis Rheum 57:234-9. 2007
    ..With the growth in patient registries in rheumatic disease research, it is important to validate the collected information. We examined the convergent validity of self-reported medication use for rheumatoid arthritis (RA)...
  47. pmc Two independent alleles at 6q23 associated with risk of rheumatoid arthritis
    Robert M Plenge
    Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nat Genet 39:1477-82. 2007
    ..We show that these two SNP associations are statistically independent, are each reproducible in the comparison of our data and WTCCC data, and define risk and protective haplotypes for rheumatoid arthritis at 6q23...
  48. doi request reprint Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis
    Altan Ercan
    Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 62:2239-48. 2010
    ..To examine the association between aberrant IgG galactosylation and disease parameters in rheumatoid arthritis (RA)...
  49. ncbi request reprint Rituximab as therapy for refractory polymyositis and dermatomyositis
    Erika H Noss
    Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women s Hospital, and Harvard University School of Medicine, Boston, Massachusetts and The Center for Rheumatology, Albany, New York, USA
    J Rheumatol 33:1021-6. 2006
    ..Thus, short-term beneficial effects with rituximab were observed in patients with DM and PM. However, the need for retreatment did not correlate with levels of CD19+ cells...
  50. ncbi request reprint Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center
    Sandeep K Agarwal
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Arthritis Rheum 53:872-8. 2005
    ..To investigate the pattern of use of infliximab with an emphasis on treatment escalation and the durability of infliximab use in the management of rheumatoid arthritis (RA) in an academic setting...
  51. doi request reprint Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
    Eli A Stahl
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Nat Genet 42:508-14. 2010
    ..An additional 11 SNPs replicated at P < 0.05, many of which are validated autoimmune risk alleles, suggesting that most represent genuine rheumatoid arthritis risk alleles...
  52. doi request reprint Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy
    Samuel M Behar
    Brigham and Women s Hospital, Boston, MA 02492, USA
    J Rheumatol 36:546-51. 2009
    ..We evaluated the T-SPOT.TB assay to identify latent tuberculosis infection (LTBI) in patients with rheumatic disease receiving immunosuppressive medication including tumor necrosis factor (TNF) antagonists...
  53. ncbi request reprint Etanercept in the treatment of adult patients with Still's disease
    M Elaine Husni
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Arthritis Rheum 46:1171-6. 2002
    ..To evaluate the safety and efficacy of etanercept in the treatment of adult patients with Still's disease...
  54. ncbi request reprint Infections and anti-tumor necrosis factor alpha therapy
    Todd Ellerin
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Arthritis Rheum 48:3013-22. 2003
  55. ncbi request reprint Prospective studies of thyroid function in patients receiving gold therapy
    S J Mandel
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Thyroid 5:113-6. 1995
    ..The most likely explanation for this is that gold principally accumulates in the Kupffer cells and renal cortex and these cells do not express Type I deiodinase...
  56. ncbi request reprint Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders
    Isao Matsumoto
    Joslin Diabetes Center and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    Arthritis Rheum 48:944-54. 2003
    ..We evaluated the generality of these observations in cohorts of patients with 12 different arthritic and chronic autoimmune diseases and in population-matched healthy control subjects...
  57. pmc Platelets amplify inflammation in arthritis via collagen-dependent microparticle production
    Eric Boilard
    Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Science 327:580-3. 2010
    ..Thus, these findings demonstrate a previously unappreciated role for platelets and their activation-induced microparticles in inflammatory joint diseases...
  58. pmc A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis
    Eric Boilard
    Division of Rheumatology, Immunology and Allergy and Partners Asthma Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    EMBO Mol Med 2:172-87. 2010
    ..These observations identify a novel anti-inflammatory function for a PLA2 and identify group V sPLA2 as a potential biotherapeutic for treatment of immune-complex-mediated inflammation...
  59. ncbi request reprint Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
    Stanley Cohen
    Department of Rheumatology, St Paul Medical Center, Dallas, Texas 75235, USA
    Arthritis Rheum 46:614-24. 2002
    ..To evaluate the efficacy and safety of anakinra in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA)...
  60. ncbi request reprint Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal
    Gabriela Schmajuk
    Stanford University, Palo Alto, California, USA
    Arthritis Rheum 57:928-34. 2007
    ..Our objective was to determine the rate and predictors of DMARD use in a cohort of elderly patients with RA...
  61. ncbi request reprint Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations
    Joel M Kremer
    The Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 48:1493-9. 2003
    ....
  62. ncbi request reprint Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies
    Michael H Schiff
    Denver Arthritis Clinic, University of Colorado, Denver, Colorado 80230, USA
    Drugs Aging 23:167-78. 2006
    ....
  63. ncbi request reprint Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Ther 25:1700-21. 2003
    ....
  64. ncbi request reprint Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience
    Larry W Moreland
    Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294 7201, USA
    J Rheumatol 33:854-61. 2006
    ..To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug (DMARD) refractory rheumatoid arthritis (RA)...
  65. pmc Common variants at CD40 and other loci confer risk of rheumatoid arthritis
    Soumya Raychaudhuri
    Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nat Genet 40:1216-23. 2008
    ..1 x 10(-7) overall), CDK6 (rs42041, P = 0.010 replication, P = 4.0 x 10(-6) overall), PRKCQ (rs4750316, P = 0.0078 replication, P = 4.4 x 10(-6) overall), and KIF5A-PIP4K2C (rs1678542, P = 0.0026 replication, P = 8.8 x 10(-8) overall)...
  66. ncbi request reprint When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
    Josef S Smolen
    Ann Rheum Dis 67:1497-8. 2008
  67. ncbi request reprint Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate
    Alex Parker
    Millennium Pharmaceuticals Inc, Cambridge, Massachusetts, USA
    J Rheumatol 34:1817-22. 2007
    ..We analyzed association of gene expression with disease activity, rheumatoid factor (RF), age, sex, disease duration, treatment modality, and clinical response...
  68. ncbi request reprint Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists
    Theodore Pincus
    Arthritis Rheum 46:851-4. 2002
  69. doi request reprint HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software
    Louise Royle
    Department of Biochemistry, Glycobiology Institute, University of Oxford, Oxford OX1 3QU, UK
    Anal Biochem 376:1-12. 2008
    ..This technology is also suitable for preparing released glycans for other analytical techniques. Here we demonstrate its application to rheumatoid arthritis using 5 microl of patient serum...